RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates [PDF]
Sleep Medicine: XObjective/Background: Preference for extended-release, once-nightly sodium oxybate (ON-SXB, FT218) vs twice-nightly immediate-release (IR) oxybate was assessed in participants switching from IR oxybate to ON-SXB in an open-label/switch study, RESTORE ...
John Harsh, Sally Ibrahim
exaly +7 more sources
How once-nightly sodium oxybate is processed in the body in healthy volunteers: a plain language summary [PDF]
Journal of Comparative Effectiveness ResearchWhat is this summary about? This is a plain language summary of an article originally published in the journal Sleep Medicine. Narcolepsy is a sleep condition in which people have periods of extreme sleepiness during the day.
Richard Bogan
exaly +6 more sources
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary [PDF]
Journal of Comparative Effectiveness Research, 2023 What is this summary about? This is a plain language summary of a published article in the journal CNS Drugs. Narcolepsy is a rare sleep condition.
Thomas Roth, Clete Kushida
exaly +4 more sources
Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary [PDF]
Journal of Comparative Effectiveness ResearchWhat is this summary about? This is a plain language summary of a published article in the journal Sleep. Narcolepsy is a sleep condition that has 2 different subtypes: narcolepsy type 1 and narcolepsy type 2. These are called NT1 and NT2 for short.
Richard Bogan +2 more
exaly +4 more sources
Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of Narcolepsy. [PDF]
J Sleep ResABSTRACT Data from the REST‐ON trial were not available before the 2021 American Academy of Sleep Medicine (AASM) clinical practice guideline update, which included a literature review through August 2020. This post hoc analysis from REST‐ON assessed participants who achieved clinically significant improvements on
Ortiz LE +7 more
europepmc +5 more sources
Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial [PDF]
Sleep Medicine: XBackground: In the REST-ON clinical trial (NCT02720744), mean sleep latency on the Maintenance of Wakefulness Test (MWT) was significantly improved with extended-release once-nightly sodium oxybate (ON-SXB) vs placebo (P
Michael J. Thorpy +6 more
doaj +3 more sources
Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial [PDF]
Sleep Medicine: XBackground: Once-nightly sodium oxybate (ON-SXB), an extended-release oxybate formulation, yielded significant (P
Michael J. Thorpy +5 more
doaj +3 more sources
Once-Nightly Pregabalin for Co-Occurring Nightmares, Poor Sleep, and Headaches: A Case Series [PDF]
Nature and Science of SleepJames H Bates,1 Sophia Brooke Rosin,2 Joshua A Tobin1,31University of Arizona College of Medicine – Phoenix, Phoenix, AZ, USA; 2University of Michigan, Ann Arbor, MI, USA; 3Banner - University Medical Center Phoenix, Neurosciences Institute, Phoenix, AZ,
Bates JH, Rosin SB, Tobin JA
doaj +3 more sources
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy [PDF]
Sleep, 2022 Study Objectives To assess the efficacy and safety of FT218, a novel once-nightly formulation of sodium oxybate (ON-SXB), in patients with narcolepsy in the phase 3 REST-ON trial.
Clete Kushida +2 more
exaly +3 more sources
Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al. [PDF]
Sleep, 2022 FT218 is an investigational, once-nightly, modified-release formulation of sodium oxybate (SO). SO effectively treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. Current approved SO formulations, at effective doses of 6, 7.5, and 9 g, require twice-nightly divided dosing, with the first dose taken at bedtime and the second 2.
Skobieranda F, Candler S, Macfadden W.
europepmc +4 more sources